Edition:
United Kingdom

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

22.44USD
13 Dec 2017
Change (% chg)

$1.37 (+6.50%)
Prev Close
$21.07
Open
$21.08
Day's High
$22.73
Day's Low
$21.08
Volume
196,528
Avg. Vol
140,361
52-wk High
$24.50
52-wk Low
$10.44

Latest Key Developments (Source: Significant Developments)

Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Cytomx Therapeutics Inc ::CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC.CYTOMX THERAPEUTICS INC - ‍IND ACCEPTANCE RESULTS IN A $10 MILLION MILESTONE PAYMENT TO CYTOMX​.CYTOMX THERAPEUTICS INC - ‍BRISTOL-MYERS SQUIBB HAS RECEIVED ACCEPTANCE OF IND FROM U.S. FDA FOR A CTLA-4-DIRECTED PROBODY THERAPEUTIC​.  Full Article

CytomX reports Q3 loss per share $‍0.28​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - CytomX Therapeutics Inc :CytomX announces third quarter 2017 financial results and operational progress.Q3 revenue $24.1 million versus $3.5 million.Q3 revenue view $17.5 million -- Thomson Reuters I/B/E/S.CytomX Therapeutics Inc qtrly loss per share $‍0.28​.  Full Article

CytomX says clinical candidate probody from Bristol-Myers Squibb collaboration selected
Tuesday, 13 Dec 2016 

CytomX Therapeutics Inc : CytomX announces selection by Bristol-Myers Squibb of first clinical candidate probody from collaboration . Upon selection of third and fourth targets, Bristol-Myers Squibb paid CytomX selection payments .Achieving this milestone results in a $2 million payment to CytomX.  Full Article

Cytomx announces second quarter 2016 financial results
Wednesday, 3 Aug 2016 

Cytomx Therapeutics Inc : Cytomx announces second quarter 2016 financial results . Qtrly total revenues $3.1 million versus $2 million . Cx-072 ind remains on track to be filed in second half of 2016 .Qtrly loss per share $0.39.  Full Article

CytomX Therapeutics Inc expects 2016 net cash utilization of $20 mln-$25 mln
Friday, 6 May 2016 

Cytomx Therapeutics : CytomX announces first quarter 2016 financial results . CytomX Therapeutics Inc says has updated its financial guidance and expects net cash utilization of $20.0 to $25.0 million in 2016 .Maintaining its guidance that its existing capital resources will be sufficient to fund its anticipated operations through 2018.  Full Article

AbbVie and CytomX announce strategic collaboration for Probody Drug Conjugates
Thursday, 21 Apr 2016 

CytomX Therapeutics:AbbVie and CytomX Therapeutics, Inc. announced that they have entered into a collaboration to co-develop and co-commercialize Probody(tm) Drug Conjugates against CD71, also known as transferrin receptor 1.Under the terms of the agreement, CytomX and AbbVie will co-develop a Probody drug conjugate against CD71, with CytomX leading pre-clinical and early clinical development.AbbVie will lead later development and commercialization, with global late-stage development costs shared between the two companies.CytomX will receive an upfront payment of $30 million and is eligible to receive up to $470 million in development, regulatory and commercial milestones, pending the achievement of pre-determined outcomes.AbbVie will lead global commercial activities with CytomX eligible to receive a profit share in the U.S. and tiered double-digit royalties on net product sales outside of the U.S. CytomX retains an option to co-promote in the U.S.AbbVie also receives exclusive worldwide rights to develop and commercialize Probody drug conjugates against up to two additional, undisclosed targets.Should AbbVie ultimately pursue these targets, CytomX is eligible to receive additional milestone and royalty payments per target on any resulting products.  Full Article

BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic

* CYTOMX THERAPEUTICS ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTLA-4 PROBODY THERAPEUTIC